WST (STOCKS)
West Pharmaceutical Services, Inc.
$346.160000
-6.130000 (-1.74%)
Prev close: $352.290000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Eric Mark Green
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $24,657.29M
- Employees
- 10,600
- P/E (TTM)
- 45.04
- P/B (TTM)
- 8.29
- Dividend Yield
- 24.98%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
14
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$2.37 | $2.10 | +0.2683 | +12.77% |
|
Mar 2026 (Q1)
|
$2.13 | $1.69 | +0.4365 | +25.78% |
|
Dec 2025 (Q4)
|
$2.04 | $1.85 | +0.1894 | +10.23% |
|
Sep 2025 (Q3)
|
$1.96 | $1.70 | +0.2616 | +15.40% |
Financial Statements
| Revenues | $3.33B |
| Benefits Costs and Expenses | $2.63B |
| Cost Of Revenue | $2.10B |
| Costs And Expenses | $2.63B |
| Gross Profit | $1.22B |
| Operating Expenses | $543.40M |
| Selling, General, and Administrative Expenses | $426.80M |
| Research and Development | $74.40M |
| Other Operating Expenses | $42.20M |
| Operating Income/Loss | $680.40M |
| Income/Loss Before Equity Method Investments | $693.60M |
| Income/Loss From Continuing Operations After Tax | $549.40M |
| Income/Loss From Continuing Operations Before Tax | $693.60M |
| Income/Loss From Equity Method Investments | $15.50M |
| Income Tax Expense/Benefit | $144.20M |
| Net Income/Loss | $564.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $564.90M |
| Net Income/Loss Available To Common Stockholders, Basic | $564.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $7.87 |
| Diluted Earnings Per Share | $7.81 |
| Basic Average Shares | 143,600,000 |
| Diluted Average Shares | 144,500,000 |
| Assets | $4.08B |
| Current Assets | $1.81B |
| Inventory | $447.40M |
| Other Current Assets | $1.36B |
| Noncurrent Assets | $2.27B |
| Fixed Assets | $1.69B |
| Intangible Assets | $6.40M |
| Other Non-current Assets | $576.20M |
| Liabilities | $1.09B |
| Current Liabilities | $640.50M |
| Accounts Payable | $252.70M |
| Other Current Liabilities | $387.80M |
| Noncurrent Liabilities | $445.70M |
| Long-term Debt | $202.90M |
| Other Non-current Liabilities | $242.80M |
| Equity | $2.99B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $2.99B |
| Liabilities And Equity | $4.08B |
| Net Cash Flow From Operating Activities | $662.20M |
| Net Cash Flow From Operating Activities, Continuing | $662.20M |
| Net Cash Flow From Investing Activities | -$225.30M |
| Net Cash Flow From Investing Activities, Continuing | -$225.30M |
| Net Cash Flow From Financing Activities | -$496.70M |
| Net Cash Flow From Financing Activities, Continuing | -$496.70M |
| Exchange Gains/Losses | -$14.10M |
| Net Cash Flow | -$73.90M |
| Net Cash Flow, Continuing | -$59.80M |
| Comprehensive Income/Loss | $513.20M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $513.20M |
| Other Comprehensive Income/Loss | $513.20M |
| Other Comprehensive Income/Loss Attributable To Parent | -$51.70M |